(Q36835812)

16 August 2017

1 reference

title

Molecular mechanisms of drug resistance in acute myeloid leukaemia (English)

1 reference

16 August 2017

1 reference

Donal P McLornan

1

1 reference

16 August 2017

Mary Frances McMullin

series ordinal

2

1 reference

16 August 2017

Patrick Johnston

series ordinal

3

1 reference

16 August 2017

Daniel B Longley

series ordinal

4

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 June 2007

1 reference

Expert Opinion on Drug Metabolism & Toxicology

16 August 2017

1 reference

16 August 2017

3

1 reference

16 August 2017

3

1 reference

16 August 2017

363-377

1 reference

Molecular genetics of human leukemias: new insights into therapy

16 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

Proposals for the Classification of the Acute Leukaemias French-American-British (FAB) Co-operative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

The World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

New strategies for the treatment of acute myeloid leukemia including antibodies and other novel agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

Chromosomal location of human P-glycoprotein gene sequences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

MDR1 gene expression and treatment outcome in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

A multidrug resistance transporter from human MCF-7 breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

ABCA3 as a possible cause of drug resistance in childhood acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

MRP3, BCRP, and P-glycoprotein activities are prognostic factors in adult acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

Breast cancer resistance protein in drug resistance of primitive CD34+38- cells in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

Cyclosporin A is a broad-spectrum multidrug resistance modulator

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

Cytosine arabinoside transport and metabolism in acute leukemias and T cell lymphoblastic lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

Deoxycytidine kinase and cN-II nucleotidase expression in blast cells predict survival in acute myeloid leukaemia patients treated with cytarabine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

Deoxycytidine kinase expression and activity in patients with resistant versus sensitive acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

In vitro leukemia cell models of Ara-C resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

A possible role for methotrexate in the treatment of childhood acute myeloid leukaemia, in particular for acute monocytic leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

Chromosome aberrations, gene mutations and expression changes, and prognosis in adult acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

Translocations of the RARalpha gene in acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

Down-stream regions of the POZ-domain influence the interaction of the t(11;17)-associated PLZF/RARalpha fusion protein with the histone-deacetylase recruiting co-repressor complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

Distinct leukemia phenotypes in transgenic mice and different corepressor interactions generated by promyelocytic leukemia variant fusion genes PLZF-RARalpha and NPM-RARalpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

Role of DNA mismatch repair in apoptotic responses to therapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

DNA repair contributes to the drug-resistant phenotype of primary acute myeloid leukaemia cells with FLT3 internal tandem duplications and is reversed by the FLT3 inhibitor PKC412.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

Polymorphisms in DNA repair genes and therapeutic outcomes of AML patients from SWOG clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

Fas ligand-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

21 January 2018

Bcl-2 family proteins

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

The biochemistry of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

The anti-apoptotic genes Bcl-X(L) and Bcl-2 are over-expressed and contribute to chemoresistance of non-proliferating leukaemic CD34+ cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

WT1 modulates apoptosis by transcriptionally upregulating the bcl-2 proto-oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

The antiapoptotic gene A1/BFL1 is a WT1 target gene that mediates granulocytic differentiation and resistance to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

Signaling pathways activated by daunorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

Fas ligand-independent, FADD-mediated activation of the Fas death pathway by anticancer drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

Prognostic significance of Fas (CD95) and TRAIL receptors (DR4/DR5) expression in acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

Fas, Fas-associated death domain-like interleukin 1beta-converting enzyme-like inhibitory protein, and apoptotic features of elderly acute myeloid leukemia based on response to induction chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

Fas receptor-Fas ligand system is independent of both CD34 status and chemosensitivity in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

Absence or low expression of fas-associated protein with death domain in acute myeloid leukemia cells predicts resistance to chemotherapy and poor outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

TRAIL receptor-2 signals apoptosis through FADD and caspase-8

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

In vitro susceptibility to TRAIL-induced apoptosis of acute leukemia cells in the context of TRAIL receptor gene expression and constitutive NF-kappa B activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

IAP proteins: blocking the road to death's door

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

Changes in apoptosis-related pathways in acute myelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

Integral role of Noxa in p53-mediated apoptotic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

PUMA, a novel proapoptotic gene, is induced by p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

A novel form of Epstein-Barr virus latency in normal B cells in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

p53 mutations in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

Trp53 loss during in vitro selection contributes to acquired Ara-C resistance in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

Nucleophosmin regulates the stability and transcriptional activity of p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

Negative regulation of p53 by nucleophosmin antagonizes stress-induced apoptosis in human normal and malignant hematopoietic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

Constitutively activated FLT3 phosphorylates BAD partially through pim-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

Mutation analysis of PTEN/MMAC1 in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

Targeting NF-kappaB activation via pharmacologic inhibition of IKK2-induced apoptosis of human acute myeloid leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

Protection of acute myeloblastic leukemia cells against apoptotic cell death by high glutathione and gamma-glutamylcysteine synthetase levels during etoposide-induced oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

Negative prognostic value of glutathione S-transferase (GSTM1 and GSTT1) deletions in adult acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

Role of gamma-glutamyl cysteine synthetase (gamma-GCS) gene expression as marker of drug sensitivity in acute myeloid leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

Induction of mitochondrial manganese superoxide dismutase confers resistance to apoptosis in acute myeloblastic leukaemia cells exposed to etoposide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

Stem cell factor as a survival and growth factor in human normal and malignant hematopoiesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

The Wnt/Wg signal transducer beta-catenin controls fibronectin expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

Constitutive activation of the Wnt/beta-catenin signalling pathway in acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

A crosstalk between the Wnt and the adhesion-dependent signaling pathways governs the chemosensitivity of acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

Epigenetic treatment of hematopoietic malignancies: in vivo targets of demethylating agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

Syntheses and biological activities of 3'-azido disaccharide analogues of daunorubicin against drug-resistant leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

The 4'-O-benzylated doxorubicin analog WP744 overcomes resistance mediated by P-glycoprotein, multidrug resistance protein and breast cancer resistance protein in cell lines and acute myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

Identification of a molecular signature predictive of sensitivity to differentiation induction in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

Mapping normal and cancer cell signalling networks: towards single-cell proteomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

Single cell profiling of potentiated phospho-protein networks in cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

Perspectives of proteomics in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.363

Increased IkappaB kinase activity is associated with activated NF-kappaB in acute myeloid blasts

21 January 2018

1 reference

5 June 2022

https://opencitations.net/index/coci/api/v1/citations/10.1038/SJ.LEU.2402641

Identifiers

DOI

10.1517/17425255.3.3.363

1 reference

16 August 2017

1 reference